T hromboembolic complications are the most common cause of morbidity after neuroendovascular procedures. 1 The risk of these complications is particularly high after stentassisted coiling (SAC) or pipeline embolization device (PED) placement and is reported to occur in 4% to 15% of cases. 2, 3 This can be attributed to the thromobogenicity of intra-arterial devices, longer procedure times, and complexity of the procedure when compared with primary coil embolization.
Intraprocedural thrombosis poses a formidable challenge. Concern for postprocedural hemorrhage may lead to under treatment with antiplatelet and thrombolytic agents, which may have deleterious consequences. 1 Intravenous abciximab and eptifibatide have previously been shown to be safe and effective in the treatment of intraprocedural thrombosis. 4, 5 However, to our knowledge, the effect of these 2 drugs has never been compared in clinical practice and was rarely assessed in the setting of SAC and PED placement. The aim of this study was to identify predictors of ischemic stroke after treatment of intraprocedural thrombosis after SAC and PED placement.
Methods
A retrospective analysis of intracranial aneurysms treated with SAC and PED placement between 2007 and 2016 at 4 academic institutions was performed. Procedures that were complicated by intraprocedural thrombosis were selected (for more details, see Methods in the online-only Data Supplement).
Background and Purpose-Intraprocedural thrombosis poses a formidable challenge during neuroendovascular procedures because the risks of aggressive thromboembolic treatment must be balanced against the risk of postprocedural hemorrhage. The aim of this study was to identify predictors of ischemic stroke after intraprocedural thrombosis after stent-assisted coiling and pipeline embolization device placement. Methods-A retrospective analysis of intracranial aneurysms treated with stent-assisted coiling or pipeline embolization device placement between 2007 and 2016 at 4 major academic institutions was performed to identify procedures that were complicated by intraprocedural thrombosis. Results-Intraprocedural thrombosis occurred in 34 (4.6%) procedures. Postprocedural ischemic stroke and hemorrhage occurred in 20.6% (7/34) and 11.8% (4/34) of procedures complicated by intraprocedural thrombosis, respectively. Current smoking was an independent predictor of ischemic stroke. There was no statistically significant difference in the rate of ischemic stroke or postprocedural hemorrhage with the use of abciximab compared with the use of eptifibatide in treatment of intraprocedural thrombosis. Conclusions-Current protocols for treatment of intraprocedural thrombosis associated with placement of intra-arterial devices were effective in preventing ischemic stroke in ≈80% of cases. Current smoking was the only independent predictor of ischemic stroke. 
Angiographic and Clinical Outcome
Postprocedural imaging was performed at the discretion of the individual institutions and was only obtained because of clinical concern. Routine screening for clinically silent ischemic strokes was not performed. Only ischemic strokes in the territory of the treated vessel were included. An ischemic stroke was considered symptomatic if the patient experienced neurological signs and symptoms corresponding to imaging findings of ischemia within 30 days of the procedure. Hemorrhagic complications were identified intraprocedurally as contrast extravasation on digital subtraction angiography or on postprocedure imaging obtained because of clinical concern. In contrast to ischemic complications, all vascular territories were included.
Results

Patients and Aneurysms Characteristics
Six hundred and eighty-four patients underwent a total of 739 SAC and PED procedures for treatment of 802 aneurysms. Of these, 34 (4.6%; median age 57 years, male-to-female ratio was 1:16) procedures were complicated by intraprocedural thrombosis and were included. Current smoking status was present in 38.2% of the procedures complicated by intraprocedural thrombosis (for more details, see Table I in the onlineonly Data Supplement).
Intraprocedural Thrombosis
Of the 34 procedures complicated by thrombosis, thrombosis was encountered within the treated vessel, resulting in complete vascular occlusion, in 29.4% (10/34) of the procedures. Intravenous eptifibatide was used in 50% (17/34) and intravenous abciximab in 50% (17/34) of the procedures. Additional heparin (2000 IU) and intra-arterial tPA (3-4 mg) were given in 17.6% (6/34) and 8.8% (3/34) of cases, respectively. Complete intraprocedural recanalization was observed in 82.3% (28/34) overall and 88.2% (15/17) and 76.5% (13/17) of cases after eptifibatide and abciximab administration, respectively (P=0.368). Postprocedural ischemic stroke occurred in 20.6% (7/34) of cases after intraprocedural thrombosis, despite treatment. Postprocedural hemorrhage occurred in 11.8% (4/34) of cases after treatment of intraprocedural thrombosis; a sequela occurred in 17.6% (3/17) of cases treated with eptifibatide and 5.9% (1/17) of cases treated with abciximab (P=0.287).
Predictors of Ischemic Stroke After Treatment of Intraprocedural Thrombosis
Younger age (P=0.045), current smoking (P=0.043), and incomplete intraprocedural recanalization (0.049) were associated with a significantly higher risk of postprocedural stroke on univariable analysis. The use of abciximab compared with eptifibatide (P=0.671) had no significant effect on the stroke rate. Similarly, the addition of heparin (P=0.793) or intra-arterial tPA (P=0.356) had no significant effect. On multivariable analysis, current smoking was an independent predictor of postprocedural ischemic stroke (odds ratio, 11.8; 95% confidence interval, 1.06-144.1; P=0.05; for more details please see Table II in the online-only Data Supplement).
Discussion
There is no consensus in the neurointerventional literature regarding the optimal agent for the treatment of acute periprocedural thromboembolic complications after stents or PED placement in treatment of intracranial aneurysms. The only approved medication to date for acute occlusion of cerebral vessels is the intravenous administration of tPA. 1 However, the use of this agent during intra-arterial procedures must be balanced against the high risk of intracranial hemorrhage and low recanalization rate. 1 The literature suggests that abciximab (irreversible GP IIb/IIIa monocloncal antibody) may be more effective in the treatment of intraprocedural thrombosis, when compared with tPA, with recanalization rates of ≤86%.
1 The risk of hemorrhage also seems to be lower, ranging from 0% to 5%. 1, 4 Both intravenous and intra-arterial administration of abciximab have shown equal safety and efficacy the in treatment of intraprocedural thrombosis. 1, 6 Eptifibatide and tirofiban (reversible GP IIb/IIIa antagonists) have also been used intravenously for the treatment of intraprocedural thrombosis with comparable efficacy and safety. 5, 7 In this study, there was no statistically significant difference between abciximab compared with eptifibatide in reducing the rate of ischemic stroke after treatment of intraprocedural thrombosis related to SAC or PED placement. Current smoking was the only independent predictor of postprocedural ischemic stroke.
For details on the limitations of the study, see Limitations in the online-only Data Supplement.
Conclusions
Current protocols for the treatment of intraprocedural thrombosis associated with placement of intra-arterial devices were effective in preventing ischemic stroke in ≈80% of cases. Current smoking was the only independent predictor of ischemic stroke.
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